Acquisition by Bryan Nancy of 22645 shares of AIM ImmunoTech at 0.23 subject to Rule 16b-3

AIM Stock  USD 0.22  0  2.23%   
About 56% of all AIM ImmunoTech's investors are looking to take a long position. The analysis of the overall investor sentiment regarding AIM ImmunoTech suggests that some traders are interested. AIM ImmunoTech's investing sentiment overview a quick insight into current market opportunities from investing in AIM ImmunoTech. Many technical investors use AIM ImmunoTech stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by AIM ImmunoTech Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

AIM ImmunoTech Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards AIM ImmunoTech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

AIM ImmunoTech Fundamental Analysis

We analyze AIM ImmunoTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AIM ImmunoTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AIM ImmunoTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Market Capitalization

Market Capitalization Comparative Analysis

AIM ImmunoTech is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

AIM ImmunoTech Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AIM ImmunoTech stock to make a market-neutral strategy. Peer analysis of AIM ImmunoTech could also be used in its relative valuation, which is a method of valuing AIM ImmunoTech by comparing valuation metrics with similar companies.

Peers

AIM ImmunoTech Related Equities

JAGXJaguar Animal   24.24   
0%
32.0%
KPRXKiora Pharmaceuticals   3.41   
0%
4.0%
APMAptorum Group   2.68   
0%
3.0%
AKTXAkari Therapeutics   1.00   
0%
1.0%
TNXPTonix Pharmaceuticals   0.25   
1.0%
0%
SLNOSoleno Therapeutics   0.30   
1.0%
0%
PULMPulmatrix   0.67   
1.0%
0%
CAPRCapricor Therapeutics   1.14   
1.0%
0%
VRAXVirax Biolabs   1.63   
2.0%
0%
BCDABiocardia   2.58   
3.0%
0%
VXRTVaxart   7.35   
9.0%
0%
FBRXForte Biosciences   7.59   
10.0%
0%
REVBRevelation Biosciences   9.78   
13.0%
0%
CLRBCellectar Biosciences   73.97   
100.0%
0%
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out AIM ImmunoTech Hype Analysis, AIM ImmunoTech Correlation and AIM ImmunoTech Performance.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.47)
Revenue Per Share
0.004
Quarterly Revenue Growth
0.19
Return On Assets
(0.80)
Return On Equity
(1.55)
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.